This is a first-in-human study. The main goal of this study is to assess the safety and tolerability of mRNA-4359 given alone and in combination with pembrolizumab.
The main purpose of this study is to test how safe these drugs are, and how well the body deals with effects of mRNA-4359 when it is given alone or in combination with pembrolizumab. The goal is to find a safe and acceptable dose in people with locally advanced, metastatic, or relapsed cancer and to find how the body deals with the study intervention at different dose levels of mRNA-4359.
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study.
Principal Investigator